We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Jourdan | LSE:JDR | London | Ordinary Share | GB00B0STXK93 | ORD GBP1 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 200.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMJDR RNS Number : 9611R Jourdan PLC 08 May 2009 8 May 2009 Jourdan plc Disposal of the business of John Corby Limited The Board of Jourdan plc ("Jourdan" or the "Company") is pleased to announce that the Company has today sold the business, fixed assets and stock of John Corby Limited ("Corby") for a total consideration of approximately GBP700,000. Corby is a wholly owned subsidiary company involved in the manufacturer of trouser presses. The consideration comprises an initial cash payment of GBP200,000 which has been received on completion and further monthly cash payments over the next 12 months. The sale price reflects the net assets of the business plus goodwill of GBP75,000.Corby generated sales in the six months to December 2008 of GBP1,497,000. This planned disposal is consistent with Jourdan's transformation from a broadly-based industrial manufacturing company to a specialist medical packaging business. Jourdan is now the leading UK manufacturer and supplier of single-use sterilisation packaging material to the medical and healthcare industry. Like for like sales in the first nine months of the year are well ahead of last year and this latest disposal will further reduce the Company's bank debt, leaving the Company well positioned to take advantage of any further opportunities. David Abell, Chairman, stated "The disposal of the Corby business will now allow Jourdan to focus on the medical packaging businesses at Westfield Medical and Clinipak, both of which are continuing to perform strongly, partly because of a substantial increase in sales to their eighty export markets helped by the massive devaluation of sterling." Contact: Jourdan plc David Abell, Chairman Tel: 01476 403456 Charles Stanley Securities Tel: 020 7149 6000 Nominated Adviser & Broker Russell Cook / Carl Holmes This information is provided by RNS The company news service from the London Stock Exchange END DISEADSPESLNEFE
1 Year Jourdan Chart |
1 Month Jourdan Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions